Nivolumab

Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)
Margaret Callahan, Asim Amin, Frederic J Kaye, Michael A Morse, Matthew H Taylor, Katriina J Peltola, Padmanee Sharma, Eileen M O'Reilly, Stephanie Meadows Shropshire, Shaun O'Brien, Marina Tschaika, Dung T Le

Journal for ImmunoTherapy of Cancer Feb 2024, 12 (2) e007883; DOI: 10.1136/jitc-2023-007883
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Claire Quaghebeur, Bjørnar Gilje, Beate Boge, Andrea Gombos, Ragnhild Sørum Falk, Randi R. Mathiesen, Lars Julsrud, Øystein Garred, Hege G. Russnes, Ragnhild Reehorst Lereim, Sudhir Kumar Chauhan, Ole Christian Lingjærde, Claire Dunn, Bjørn Naume, Jon Amund Kyte

Journal for ImmunoTherapy of Cancer Jan 2024, 12 (1) e007990; DOI: 10.1136/jitc-2023-007990
Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer
Douglas G McNeel, Hamid Emamekhoo, Jens C Eickhoff, Christos E Kyriakopoulos, Ellen Wargowski, Tommaso P Tonelli, Laura E Johnson, Glenn Liu

Journal for ImmunoTherapy of Cancer Dec 2023, 11 (12) e008067; DOI: 10.1136/jitc-2023-008067
Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
Jie He, Natallia Kalinava, Parul Doshi, Dean C Pavlick, Lee A Albacker, Ericka M Ebot, Hanna Tukachinsky, James Pratt, Gina Fusaro, Geoffrey R Oxnard, George Green, David Fabrizio, Jonathan Baden

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (11) e007339; DOI: 10.1136/jitc-2023-007339
Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck
Jennifer M Johnson, Ioannis A Vathiotis, Larry A Harshyne, Ayesha Ali, Voichita Bar Ad, Rita Axelrod, Emily Lorber, Joseph Curry, David M Cognetti, Adam J Luginbuhl, Madalina Tuluc, Scott Keith, Mỹ G Mahoney, Athanassios Argiris

Journal for ImmunoTherapy of Cancer Aug 2023, 11 (8) e007141; DOI: 10.1136/jitc-2023-007141
Management of immune-related cutaneous adverse events with dupilumab
Alyce Mei-Shiuan Kuo, Stephanie Gu, Joseph Stoll, Andrea P Moy, Stephen W Dusza, Allison Gordon, Elena C Haliasos, Yelena Janjigian, Lukas Kraehenbuehl, Elizabeth A Quigley, Paul Chapman, Mario E Lacouture, Alina Markova

Journal for ImmunoTherapy of Cancer Jun 2023, 11 (6) e007324; DOI: 10.1136/jitc-2023-007324
Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
Cathrine Lund Lorentzen, Julie Westerlin Kjeldsen, Eva Ehrnrooth, Mads Hald Andersen, Inge Marie Svane

Journal for ImmunoTherapy of Cancer May 2023, 11 (5) e006755; DOI: 10.1136/jitc-2023-006755
Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade
Luke Frankiw, Arun Singh, Cole Peters, Begoña Comin-Anduix, Beata Berent-Maoz, Mignonette Macabali, Kiana Shammaie, Crystal Quiros, Paula Kaplan-Lefko, Ignacio Baselga Carretero, Antoni Ribas, Theodore Scott Nowicki

Journal for ImmunoTherapy of Cancer May 2023, 11 (5) e006930; DOI: 10.1136/jitc-2023-006930
Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report
Masood Sadaat, Sekwon Jang

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 49; DOI: 10.1186/s40425-018-0365-3
Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment
Léa Paolini, Caroline Poli, Simon Blanchard, Thierry Urban, Anne Croué, Marie-Christine Rousselet, Sarah Le Roux, Nathalie Labarrière, Pascale Jeannin, José Hureaux

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 52; DOI: 10.1186/s40425-018-0372-4

Main menu

Nivolumab

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Nivolumab

Pages